L ung cancer is the most common cause of cancer-related deaths worldwide and non-small cell lung cancer (NSCLC) comprising a variety of histological subtypes such as adenocarcinoma, squamous-cell carcinoma, large-cell carcinoma and bronchoalveolar carcinoma accounts for 80% of all patients with lung cancer.
ological studies suggesting an association between vitamin D deficiency and autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, diabetes mellitus, systemic lupus erythematosus, and inflammatory bowel disease. [3] As it is well-known, inflammation is often associated to carcinogenesis. [4] Vitamin D influences the development of cancer through the modulation of inflammatory system by regulating cytokine levels in the microenvironment of tumor, inhibiting prostaglandins, activating mitogen-activated protein kinase phosphatase 5 (MPK5), inhibiting nuclear factor kappa B (NF-KB) signaling pathway, and inhibiting immune cells (i.e., macrophages, dendritic cells, T and B cells). [4] Serum vitamin D deficiency has been identified as a poor prognostic factor in all gastrointestinal cancers, particularly in advanced stage colon cancer and breast cancer. [5] However, the role it plays in lung cancer still remains to be elucidated. The overall survival was found to be higher in patients with Stage I and II NSCLC who were operated in summer and who received vitamin D-fortified diet than in patients who were operated on in winter and who had poor dietary intake. [6] Zhou et al. [7] reported that high plasma vitamin D levels favorably affected survival in patients with Stage Ib and II NSCLC, although this effect disappeared in patients with advanced disease. As opposed to these data, Cheng et al. [8] found no relationship between plasma vitamin D levels and lung cancer in the US population. [8] However, there is a limited number of data regarding the relationship between vitamin D status and subtypes of NSCLC and disease stage.
Serum 25(OH)D level below 20 ng/mL is defined as vitamin D deficiency. [8] In the present study, we aimed to compare 25(OH)D levels between patients with NSCLC at the time of diagnosis and healthy controls and to evaluate the differences in serum 25(OH)D levels across the subgroups and stages of NSCLC.
Methods
This retrospective study was approved by the Pamukkale University, Non-interventional Clinical Trials Ethics Committee (Decree No: 70034/Date: October 15, 2018). The study was conducted in accordance with the principles of the Declaration of Helsinki. A total of 462 patients with NSCLC who were followed and treated in three participating centers were compared with blood test date, age-and sex-matched 462 healthy controls who underwent testing for serum calcium, lactate dehydrogenase (LDH), magnesium, phosphorus, creatinine and vitamin D levels between January 2016 and June 2018. Inclusion criteria for patients were: histopathologically diagnosed as having NSCLC (adenocarcinoma, squamous cell carcinoma, bronchoalveolar, or large cell lung carcinoma). Who were already taking a vitamin D supplement or active vitamin D and who had a history of urinary tract stones both excluded from control and patient groups.
Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS) version 22.0 software (IBM Corp., Armonk, NY, USA). Descriptive data were expressed in mean and standard deviation (SD) and number and frequency. The Student's t-test was used for continuous variables and the Fisher's exact test was used for categorical variables. A p value of <0.05 was considered statistically significant.
Results
The mean age in the patient group (n=462) was 63.46±8.86 years (range, 28-85). The patient group was composed of 58 females (12.6%) and 404 males (87.4%). Histological subtypes and disease stage at the time of diagnosis are presented in Table 1 . Serum 25(OH)D, calcium, LDH and magnesium levels were significantly different between the patient and the control group (Table 2) . When the patients with NSCLC were evaluated according to the histological subtype, serum 25(OH)D was significantly lower in patients with adenocarcinoma than in patients with squamous-cell carcinoma (Table 3 ). In addition, since the number of patients in "other histology" group was less than the other groups, comparisons between the groups were made using Bonferroni corrections, with p<0.017 accepted as significant for Table 3 . When the patients were evaluated according to the clinical disease stage, a significant correlation was observed between advanced stage and decreased serum 25(OH)D and increased LDH levels (Table 4) .
Discussion
Experimental studies have shown that circulating 25(OH)D decreases cellular proliferation and increases apoptosis in NSCLC. [9] It has been also shown that vitamin D inhibits the growth of lung cancer metastases in experimental animal models. [10] Furthermore, it has been demonstrated to prevent the migration of tumor cells in lung cancer by inhibiting angiogenesis. [10] Immunomodulator function of vitamin D can play a role in preventing lung cancer. In lung cancer cell lines, vitamin D upregulates the protein expression by inhibiting mammalian target of rapamycin (mTOR) activity and promotes autophagia of tumor cells. [11] In addition, it prevents the development of lung cancer by upregulating the expression of superoxide dismutase 1 and 2, the major antioxidant defense system. [12] In the light of the available data based on the experimental studies, vitamin D can be suggested to have a protective effect against lung cancer.
Chemoprevention studies in breast and colon cancer have revealed that vitamin D has an antitumor activity. [13] In a meta-analysis by Zhang et al. [14] involving 290,000 cases, high vitamin D levels were shown to reduce the risk of NS-CLC. However, this meta-analysis found no relationship between high vitamin D supplementation and a reduction in the risk of NSCLC. In a meta-analysis by Liu et al. [15] reported that vitaminD-fortified diet significantly reduced the risk of NSCLC and higher serum vitamin D level significantly reduced NSCLC-related mortality. In a meta-analysis by Muller et al. [16] involving 20 prospective cohort studies, patients with lung cancer, serum vitamin D levels measured five years before the diagnosis of NSCLC did not differ from those of age, sex, blood test date, race, and smoking status-matched controls and the authors reported no relationship between serum vitamin D concentration and the risk of developing lung cancer. A possible relationship between vitamin D status and NSCLC still remains a hot topic attracting the attention of researchers due to conflicting results in the literature.
To date, experimental studies have evaluated the efficacy of vitamin D in various subtypes of NSCLC. Serum vitamin D suppressed the growth of tumor cells in squamous cell lung cancer, whereas it showed no effect on adenocarcinoma cell lines. [17] Similarly, vitamin D replacement study in a mouse model with squamous cell carcinoma of the lung showed that vitamin D reduced premalignant cellular proliferation, inflammation, and tumor proliferation. [18] However, the relationship between serum vitamin D status and the subtypes of NSCLC in clinical practice has not been evaluated. In our study, we found significantly lower vitamin D levels in the adenocarcinoma subgroup than in the squamous cell carcinoma subgroup. This finding can be attributed to the fact that adenocarcinoma subtype is associated with a poorer prognosis than the squamous cell carcinoma. [19] The decrease in vitamin D levels which is inversely associated with an increase in clinical stage at the time of diagnosis also supports the findings of Wang et al. [20] In their study, Akiba et al. [21] compared patients with NSCLC who received vitamin D replacement for one year after tumor surgery with the placebo group and found no significant difference than general population in terms of progression-free survival (PFS) and overall survival (OS); however, they observed a significant increase in the PFS and OS rates with vitamin D replacement in the early-stage adenocarcinoma patients. The most recent meta-analysis of 17 prospective cohort studies involving 139,000 patients also suggested that high serum vitamin D levels played a role in the prevention of lung cancer. [22] The risk of lung cancer decreased by 8% and the risk of mortality from lung cancer decreased by 7% for every 10 ng/mL increase in serum vitamin D levels. [22] Nonetheless, there are some limitations to this study. In the present study, we were only able to evaluate laboratory parameters at the time of diagnosis and, therefore, there is a need for long-term follow-up and survival analysis. However, the strength of our study is that, to the best of our knowledge, this is the most extensive study in our geographic region in terms of the number of participating patients. In addition, demonstration of a difference in serum 25(OH)D levels among the histological subtypes may also contribute to the growing body of knowledge in the literature.
In this study we found serum 25(OH)D levels were significantly lower in the patient group, and serum 25(OH)D was significantly lower in patients with adenocarcinoma than the squamous cell carcinoma.
